Sensorion and EVEON Collaborating to Develop an Injection System for the Delivery of Gene Therapy Treatments Into the Inner Ear
31 Janvier 2023 - 7:30AM
Business Wire
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering
clinical-stage biotechnology company which specializes in the
development of novel therapies to restore, treat and prevent within
the field of hearing loss disorders, and EVEON, designer and
manufacturer of custom medical devices for the preparation and
delivery of drugs, announce they have been collaborating to design
and develop an injection system for the delivery of Sensorion’s
gene therapy products to the inner ear, including OTOF-GT product
candidate.
Therapies for treating genetic hearing loss are often
challenging due to the need for delivery into the inner ear, a very
small and delicate organ embedded in the temporal bone. As part of
the collaboration, EVEON and Sensorion have been exploring ways to
optimise the delivery of gene therapies for improved efficacy and
potential patient experience which supports Sensorion’s gene
therapy programs development.
“We are really pleased to have been working with ENT surgeons
and EVEON to develop an injection system for the safe and effective
delivery of our gene therapy candidates,” said Geraldine Honnet,
MD, Chief Medical Officer of Sensorion. “Our delivery system is
intended to allow the delivery of Sensorion’s gene therapy product
candidates into the inner ear with the aim of restoring hearing in
patients suffering from hereditary monogenic forms of deafness.
Effective and safe administration is critical for gene therapies
and we need to ensure an optimal route of injection.”
“At EVEON, we are thrilled to be working with Sensorion, a
leader in hearing therapeutics,” said Vincent Tempelaere,
Chief Executive Officer at EVEON. “This new project
demonstrates the capabilities of our respective technology
platforms and enables our teams to work effectively to provide
tailor-made solutions for the delivery of new gene therapies.”
Sensorion is pursuing two gene therapy programs aimed at
correcting hereditary monogenic forms of deafness including
OTOF-GT, targeting deafness caused by mutations of the gene
encoding for otoferlin, and hearing loss related to mutations in
GJB2 gene to potentially address important hearing loss segments in
adults and children (GJB2-GT).
About Sensorion Sensorion is a pioneering clinical-stage
biotech company, which specializes in the development of novel
therapies to restore, treat and prevent hearing loss disorders, a
significant global unmet medical need.
Sensorion has built a unique R&D technology platform to
expand its understanding of the pathophysiology and etiology of
inner ear related diseases, enabling it to select the best targets
and mechanisms of action for drug candidates. Its portfolio
combines both small molecule and inner ear gene therapies
programs.
Its clinical-stage portfolio includes one Phase 2 product:
SENS-401 (Arazasetron) progressing in a planned Phase 2 Proof of
Concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity
(CIO) and, with partner Cochlear Limited, in a study of SENS-401 in
patients scheduled for cochlear implantation. A Phase 2 study of
SENS-401 was also completed in Sudden Sensorineural Hearing Loss
(SSNHL) in January 2022.
Sensorion pursues its broad strategic collaboration with
Institut Pasteur focused on the genetics of hearing. It has two
gene therapy programs aimed at correcting hereditary monogenic
forms of deafness including OTOF-GT, targeting deafness caused by
mutations of the gene encoding for otoferlin, and hearing loss
related to mutations in GJB2 gene to potentially address important
hearing loss segments in adults and children (GJB2-GT). The Company
is also working on the identification of biomarkers to improve
diagnosis of these underserved illnesses.
www.sensorion.com
About EVEON EVEON designs and develops custom devices for
preparation and delivery of advanced therapeutic treatments. We
work with practitioners and patients to provide solutions in order
to improve patient compliance and therapeutic performance. EVEON
develops your devices according to two broad approaches: custom
devices based on your specific needs or custom devices based on
Intuity® proprietary technological platforms. Certified ISO13485
company, EVEON integrates the key relevant international standards
of electromechanical devices: EN 62304 (software), cybersecurity,
EN 60601-1 (Medical electrical equipment). EVEON is also involved
in a specific French program to build with other companies, from
various economic fields, a business climate convention.
Label: SENSORION ISIN: FR0012596468 Mnemonic:
ALSEN
Disclaimer This press release contains certain
forward-looking statements concerning Sensorion and its business.
Such forward looking statements are based on assumptions that
Sensorion considers to be reasonable. However, there can be no
assurance that such forward-looking statements will be verified,
which statements are subject to numerous risks, including the risks
set forth in the 2021 full year financial report published on April
28, 2022, and available on our website and to the development of
economic conditions, financial markets and the markets in which
Sensorion operates. The forward-looking statements contained in
this press release are also subject to risks not yet known to
Sensorion or not currently considered material by Sensorion. The
occurrence of all or part of such risks could cause actual results,
financial conditions, performance or achievements of Sensorion to
be materially different from such forward-looking statements. This
press release and the information that it contains do not
constitute an offer to sell or subscribe for, or a solicitation of
an offer to purchase or subscribe for, Sensorion shares in any
country. The communication of this press release in certain
countries may constitute a violation of local laws and regulations.
Any recipient of this press release must inform oneself of any such
local restrictions and comply therewith.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230130005684/en/
Press: Charlotte Reverand | cre@eveon.eu |
www.eveon.eu
Investor Relations Noemie Djokovic Investor Relations and
Communications +33 6 76 67 98 31
ir.contact@sensorion-pharma.com
International Media Relations Consilium Strategic
Communications Matthew Cole/Jessica Hodgson +44 7593 572720 +44
7561 424788 Sensorion@consilium-comms.com
Sensorion (EU:ALSEN)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Sensorion (EU:ALSEN)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024